These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Risks and benefits of triple oral anti-thrombotic therapies after acute coronary syndromes and percutaneous coronary intervention. Alfredsson J; Roe MT Drug Saf; 2015 May; 38(5):481-91. PubMed ID: 25829216 [TBL] [Abstract][Full Text] [Related]
3. Platelet reactivity in patients receiving a maintenance dose of P2Y12-ADP receptor antagonists undergoing elective percutaneous coronary intervention. Bonello L; Laine M; Thuny F; Paganelli F; Lemesle G; Roch A; Kerbaul F; Dignat-George F; Berbis J; Frere C Int J Cardiol; 2016 Aug; 216():190-3. PubMed ID: 27179310 [TBL] [Abstract][Full Text] [Related]
4. Current status of data on cangrelor. Qamar A; Bhatt DL Pharmacol Ther; 2016 Mar; 159():102-9. PubMed ID: 26802900 [TBL] [Abstract][Full Text] [Related]
5. Strategies to Optimize Dual Antiplatelet Therapy After Coronary Artery Stenting in Acute Coronary Syndrome. Paravattil B; Elewa H J Cardiovasc Pharmacol Ther; 2017 Jul; 22(4):347-355. PubMed ID: 28587584 [TBL] [Abstract][Full Text] [Related]
6. P2Y van der Sangen NM; Küçük IT; Ten Berg JM; Beijk MA; Delewi R; den Hartog AW; Appelman Y; Verouden NJ; Kikkert WJ; Henriques JP; Claessen BE Expert Rev Cardiovasc Ther; 2022 Aug; 20(8):637-645. PubMed ID: 35916833 [TBL] [Abstract][Full Text] [Related]
7. Switching of platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Review of the literature and practical considerations. De Luca L; Capranzano P; Patti G; Parodi G Am Heart J; 2016 Jun; 176():44-52. PubMed ID: 27264219 [TBL] [Abstract][Full Text] [Related]
8. A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis. Westman PC; Lipinski MJ; Torguson R; Waksman R Cardiovasc Revasc Med; 2017 Mar; 18(2):79-85. PubMed ID: 28089137 [TBL] [Abstract][Full Text] [Related]
10. Effect of prasugrel pre-treatment strategy in patients undergoing percutaneous coronary intervention for NSTEMI: the ACCOAST-PCI study. Montalescot G; Collet JP; Ecollan P; Bolognese L; Ten Berg J; Dudek D; Hamm C; Widimsky P; Tanguay JF; Goldstein P; Brown E; Miller DL; LeNarz L; Vicaut E; J Am Coll Cardiol; 2014 Dec; 64(24):2563-2571. PubMed ID: 25524333 [TBL] [Abstract][Full Text] [Related]
11. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678 [TBL] [Abstract][Full Text] [Related]
12. Cangrelor: a novel intravenous antiplatelet agent with a questionable future. Waite LH; Phan YL; Spinler SA Pharmacotherapy; 2014 Oct; 34(10):1061-76. PubMed ID: 25123696 [TBL] [Abstract][Full Text] [Related]
13. Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis. Rafique AM; Nayyar P; Wang TY; Mehran R; Baber U; Berger PB; Tobis J; Currier J; Dave RH; Henry TD JACC Cardiovasc Interv; 2016 May; 9(10):1036-46. PubMed ID: 27198684 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study. O'Connor SA; Amour J; Mercadier A; Martin R; Kerneis M; Abtan J; Brugier D; Silvain J; Barthélémy O; Leprince P; Montalescot G; Collet JP; Circ Cardiovasc Interv; 2015 Nov; 8(11):e002786. PubMed ID: 26553698 [TBL] [Abstract][Full Text] [Related]
15. Implementation of contemporary oral antiplatelet treatment guidelines in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a report from the GReek AntiPlatelet rEgistry (GRAPE). Alexopoulos D; Goudevenos JA; Xanthopoulou I; Deftereos S; Sitafidis G; Kanakakis I; Hamilos M; Parissis H; Ntalas IV; Angelidis C; Petousis S; Vavuranakis M; Hahalis G; Stefanadis C; Int J Cardiol; 2013 Oct; 168(6):5329-35. PubMed ID: 23978364 [TBL] [Abstract][Full Text] [Related]
16. Platelet Inhibition with Ticagrelor 60 mg Versus 90 mg Twice Daily in Elderly Patients with Acute Coronary Syndrome: Rationale and Design of the PLINY THE ELDER Trial. Piccolo R; Avvedimento M; Canonico ME; Gargiulo P; Paolillo R; Conti V; Dal Piaz F; Filippelli A; Morisco C; Simonetti F; Leone A; Marenna A; Bruzzese D; Gargiulo G; Stabile E; Di Serafino L; Franzone A; Cirillo P; Esposito G Cardiovasc Drugs Ther; 2023 Oct; 37(5):1031-1038. PubMed ID: 35048203 [TBL] [Abstract][Full Text] [Related]
17. Ticagrelor Utilization in Patients With Non-ST Elevation Acute Coronary Syndromes in Romania. Cotoban AG; Udroiu CA; Vinereanu D Am J Ther; 2021 Apr; 28(3):e271-e283. PubMed ID: 33852478 [TBL] [Abstract][Full Text] [Related]
18. Characteristics of new P2Y12 inhibitors: selection of P2Y12 inhibitors in clinical practice. Golino P J Cardiovasc Med (Hagerstown); 2013 Dec; 14 Suppl 1():S22-30. PubMed ID: 24378838 [TBL] [Abstract][Full Text] [Related]